Patents Assigned to SyntheX, Inc.
  • Patent number: 11840743
    Abstract: The present disclosure provides methods to identify peptides and small molecule moieties that are able to modulate protein-protein interactions (PPIs). Some moieties can disrupt specific PPIs within a complex, or disrupt variant-specific PPIs. Some moieties can alternatively bridge between two proteins in a protein-specific or a variant-specific manner. The methods described enable generation of compounds able to modulate PPI networks within cells with implications for drug development for pathological conditions.
    Type: Grant
    Filed: May 13, 2020
    Date of Patent: December 12, 2023
    Assignee: SYNTHEX, INC.
    Inventors: Maria Soloveychik, Charly Chahwan
  • Patent number: 11780881
    Abstract: The present disclosure provides methods to treat conditions, including cancer, using compounds that can target resistant cancer cells. The compounds can be used to sensitize resistant cancer cells or decrease the proliferation of cells. The compounds can target proteins in the DNA damage repair pathway leading to a decrease in DNA damage repair and cell death.
    Type: Grant
    Filed: May 18, 2020
    Date of Patent: October 10, 2023
    Assignee: SYNTHEX, INC.
    Inventors: Charly Chahwan, Maria Soloveychik
  • Patent number: 11306306
    Abstract: The present disclosure provides methods to identify peptides and small molecule moieties that are able to functionally bridge an interaction between a target protein and an E3 ubiquitin ligase to mediate the degradation of the target protein. Some moieties can degrade specific target variants, but not others. The moieties create a neosubstrate for an E3 ligase of interest. The methods described enable generation of compounds able to selectively degrade specific targets within cells with implications for drug development for pathological conditions. The disclosure also describes the generation of modified peptides using post-translational modification enzymes, such as N-methyltransferases, prolyloligopeptidases, lactamases, hydroxylases, and dehydratases, along with methods of using the same.
    Type: Grant
    Filed: May 11, 2021
    Date of Patent: April 19, 2022
    Assignee: SYNTHEX, INC.
    Inventors: Charly Chahwan, Maria Soloveychik
  • Patent number: 10188691
    Abstract: The present disclosure provides methods to treat conditions, including cancer, using compounds that can target resistant cancer cells. The compounds can be used to sensitize resistant cancer cells or decrease the proliferation of cells. The compounds can target proteins in the DNA damage repair pathway leading to a decrease in DNA damage repair in target cells.
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: January 29, 2019
    Assignee: SyntheX, Inc.
    Inventors: Charly Chahwan, Maria Soloveychik